{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:23Z","timestamp":1788985343881,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaad.2023.11.060","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:01:25Z","timestamp":1702926085000},"page":"775-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hippeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Colston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Balagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.11.060_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"60","author":"Chan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1468-3083.2007.02424.x","article-title":"Scalp psoriasis: a review of current topical treatment options","volume":"21","author":"Papp","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.11.060_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2012.681017","article-title":"Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council","volume":"24","author":"Kragballe","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2023.11.060_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bjd.12393","article-title":"Topical treatments for chronic plaque psoriasis of the scalp: a systematic review","volume":"169","author":"Mason","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2023.11.060_bib8","series-title":"Sotyktu [package insert]","year":"2022"},{"key":"10.1016\/j.jaad.2023.11.060_bib9","series-title":"Sotyktu [package insert]","year":"2022"},{"key":"10.1016\/j.jaad.2023.11.060_bib10","series-title":"Sotyktu [product monograph]","year":"2022"},{"key":"10.1016\/j.jaad.2023.11.060_bib11","series-title":"Sotyktu [product information]","year":"2022"},{"key":"10.1016\/j.jaad.2023.11.060_bib12","series-title":"Sotyktu [summary of product characteristics]","year":"2023"},{"key":"10.1016\/j.jaad.2023.11.060_bib13","series-title":"Sotyktu [package insert]","year":"2023"},{"key":"10.1016\/j.jaad.2023.11.060_bib14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.11.060_bib15","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jaad.2023.11.060_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000051731","article-title":"Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients","volume":"203","author":"Tha\u00e7i","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2023.11.060_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.11.060_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.11.060_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223033741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223033741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:29:55Z","timestamp":1759274995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223033741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0190962223033741"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.060","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.11.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}